🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy blood pressure normalization journey — my results so far

My blood pressure normalization journey — my results so far

FranDenver Tue, Jan 9, 2024 at 7:38 AM 12 replies 2,127 viewsPage 1 of 3
This thread is more than 29 months old. Information may be outdated. Consider searching for more recent discussions.
FranDenver
Member
267
1,123
Oct 2024
Denver, CO
Jan 9, 2024 at 7:38 AM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

What I am after is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

Practical detail welcome, however dull — the duller the better.

18 13Dr.RenalNash, LipidDoc_ATL, BariatricNurseD and 15 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Jan 9, 2024 at 7:48 AM#2
FranDenver said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

I'm 48 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

15 months later: down 52 lbs, off atorvastatin, A1C from 8.4% to 5.3%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: Jan 9, 2024 at 9:48 AM
17 12HPLC_Greg, LibrarianMeg, bri_stats and 14 others
Reply Quote Save Share Report
marco_milano
Member
345
1,456
Jul 2024
Milan, IT
Jan 9, 2024 at 7:58 AM#3
labquiet_amy said:
I'm 48 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Senior perspective on cardiovascular risk: I'm 67 years old and started this journey skeptically. My geriatrician recommended it after years of failed interventions.

9 months later: down 35 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

16 11Dr.LipidDallas, alex_tucson, kevin_tulsa and 13 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
patPC_UT
Member
212
890
Nov 2024
Park City, UT
Jan 9, 2024 at 8:08 AM#4
FranDenver said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Mine went the same way, slower. Posting only so the count is not one.

15 10JessicaM_2024, TomFromTexas, mike.trainer_LA and 12 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Jan 9, 2024 at 8:59 AM#5

Adding the clinical framing, because it changes how the question reads.

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

References:
[1] Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.
Last edited: Jan 9, 2024 at 11:59 AM
14 9cory_ATX, lori_vegas, Dr.PulmRoch and 11 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register